Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines

Thomas W. Flaig; Philippe E. Spiess; Michael Abern; Neeraj Agarwal; Rick Bangs; Stephen A. Boorjian; Mark K. Buyyounouski; Kevin Chan; Sam Chang; Terence Friedlander; Richard E. Greenberg; Khurshid A. Guru; Harry W. Herr; Jean Hoffman-Censits; Amar Kishan; Shilajit Kundu; Subodh M. Lele; Ronac Mamtani; Vitaly Margulis; Omar Y. Mian; Jeff Michalski; Jeffrey S. Montgomery; Lakshminarayanan Nandagopal; Lance C. Pagliaro; Mamta Parikh; Anthony Patterson; Elizabeth R. Plimack; Kamal S. Pohar; Mark A. Preston; Kyle Richards; Wade J. Sexton; Arlene O. Siefker-Radtke; Matthew Tollefson; Jonathan Tward; Jonathan L. Wright; Mary A. Dwyer; Carly J. Cassara; Lisa A. Gurski

doi:10.6004/jnccn.2022.0041

Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines

Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman-Censits, Amar Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. MianJeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle Richards, Wade J. Sexton, Arlene O. Siefker-Radtke, Matthew Tollefson, Jonathan Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, Lisa A. Gurski

Research output: Contribution to journal › Article › peer-review

154 Scopus citations

Abstract

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.

Original language	English
Pages (from-to)	866-878
Number of pages	13
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	20
Issue number	8
DOIs	https://doi.org/10.6004/jnccn.2022.0041
State	Published - Aug 2022

Keywords

Administration, Intravesical
Carcinoma, Transitional Cell/pathology
Humans
Male
Neoplasm Invasiveness/pathology
Neoplasm Recurrence, Local/pathology
Neoplasm Staging
Urinary Bladder Neoplasms/drug therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2022.0041

Cite this

Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chan, K., Chang, S., Friedlander, T., Greenberg, R. E., Guru, K. A., Herr, H. W., Hoffman-Censits, J., Kishan, A., Kundu, S., Lele, S. M., Mamtani, R., Margulis, V., ... Gurski, L. A. (2022). Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 20(8), 866-878. https://doi.org/10.6004/jnccn.2022.0041

@article{8f236428798a4cf48b83d7837609c583,

title = "Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Gu{\'e}rin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.",

keywords = "Administration, Intravesical, Carcinoma, Transitional Cell/pathology, Humans, Male, Neoplasm Invasiveness/pathology, Neoplasm Recurrence, Local/pathology, Neoplasm Staging, Urinary Bladder Neoplasms/drug therapy",

author = "Flaig, {Thomas W.} and Spiess, {Philippe E.} and Michael Abern and Neeraj Agarwal and Rick Bangs and Boorjian, {Stephen A.} and Buyyounouski, {Mark K.} and Kevin Chan and Sam Chang and Terence Friedlander and Greenberg, {Richard E.} and Guru, {Khurshid A.} and Herr, {Harry W.} and Jean Hoffman-Censits and Amar Kishan and Shilajit Kundu and Lele, {Subodh M.} and Ronac Mamtani and Vitaly Margulis and Mian, {Omar Y.} and Jeff Michalski and Montgomery, {Jeffrey S.} and Lakshminarayanan Nandagopal and Pagliaro, {Lance C.} and Mamta Parikh and Anthony Patterson and Plimack, {Elizabeth R.} and Pohar, {Kamal S.} and Preston, {Mark A.} and Kyle Richards and Sexton, {Wade J.} and Siefker-Radtke, {Arlene O.} and Matthew Tollefson and Jonathan Tward and Wright, {Jonathan L.} and Dwyer, {Mary A.} and Cassara, {Carly J.} and Gurski, {Lisa A.}",

year = "2022",

month = aug,

doi = "10.6004/jnccn.2022.0041",

language = "English",

volume = "20",

pages = "866--878",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "8",

}

Flaig, TW, Spiess, PE, Abern, M, Agarwal, N, Bangs, R, Boorjian, SA, Buyyounouski, MK, Chan, K, Chang, S, Friedlander, T, Greenberg, RE, Guru, KA, Herr, HW, Hoffman-Censits, J, Kishan, A, Kundu, S, Lele, SM, Mamtani, R, Margulis, V, Mian, OY, Michalski, J, Montgomery, JS, Nandagopal, L, Pagliaro, LC, Parikh, M, Patterson, A, Plimack, ER, Pohar, KS, Preston, MA, Richards, K, Sexton, WJ, Siefker-Radtke, AO, Tollefson, M, Tward, J, Wright, JL, Dwyer, MA, Cassara, CJ & Gurski, LA 2022, 'Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 20, no. 8, pp. 866-878. https://doi.org/10.6004/jnccn.2022.0041

TY - JOUR

T1 - Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines

AU - Flaig, Thomas W.

AU - Spiess, Philippe E.

AU - Abern, Michael

AU - Agarwal, Neeraj

AU - Bangs, Rick

AU - Boorjian, Stephen A.

AU - Buyyounouski, Mark K.

AU - Chan, Kevin

AU - Chang, Sam

AU - Friedlander, Terence

AU - Greenberg, Richard E.

AU - Guru, Khurshid A.

AU - Herr, Harry W.

AU - Hoffman-Censits, Jean

AU - Kishan, Amar

AU - Kundu, Shilajit

AU - Lele, Subodh M.

AU - Mamtani, Ronac

AU - Margulis, Vitaly

AU - Mian, Omar Y.

AU - Michalski, Jeff

AU - Montgomery, Jeffrey S.

AU - Nandagopal, Lakshminarayanan

AU - Pagliaro, Lance C.

AU - Parikh, Mamta

AU - Patterson, Anthony

AU - Plimack, Elizabeth R.

AU - Pohar, Kamal S.

AU - Preston, Mark A.

AU - Richards, Kyle

AU - Sexton, Wade J.

AU - Siefker-Radtke, Arlene O.

AU - Tollefson, Matthew

AU - Tward, Jonathan

AU - Wright, Jonathan L.

AU - Dwyer, Mary A.

AU - Cassara, Carly J.

AU - Gurski, Lisa A.

PY - 2022/8

Y1 - 2022/8

N2 - The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.

AB - The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.

KW - Administration, Intravesical

KW - Carcinoma, Transitional Cell/pathology

KW - Humans

KW - Male

KW - Neoplasm Invasiveness/pathology

KW - Neoplasm Recurrence, Local/pathology

KW - Neoplasm Staging

KW - Urinary Bladder Neoplasms/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85136339808&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000898497800004&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2022.0041

DO - 10.6004/jnccn.2022.0041

M3 - Article

C2 - 35948037

SN - 1540-1405

VL - 20

SP - 866

EP - 878

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 8

ER -

Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this